CA3058807A1 - Protein antigens and uses thereof - Google Patents

Protein antigens and uses thereof Download PDF

Info

Publication number
CA3058807A1
CA3058807A1 CA3058807A CA3058807A CA3058807A1 CA 3058807 A1 CA3058807 A1 CA 3058807A1 CA 3058807 A CA3058807 A CA 3058807A CA 3058807 A CA3058807 A CA 3058807A CA 3058807 A1 CA3058807 A1 CA 3058807A1
Authority
CA
Canada
Prior art keywords
ebv
peptide
cell
cancer
balf5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3058807A
Other languages
English (en)
French (fr)
Inventor
Michael Steven Rooney
Original Assignee
Biontech US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech US Inc filed Critical Biontech US Inc
Publication of CA3058807A1 publication Critical patent/CA3058807A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA3058807A 2017-04-03 2018-04-03 Protein antigens and uses thereof Pending CA3058807A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762480597P 2017-04-03 2017-04-03
US201762480593P 2017-04-03 2017-04-03
US201762480596P 2017-04-03 2017-04-03
US62/480,597 2017-04-03
US62/480,593 2017-04-03
US62/480,596 2017-04-03
PCT/US2018/025933 WO2018187356A2 (en) 2017-04-03 2018-04-03 Protein antigens and uses thereof

Publications (1)

Publication Number Publication Date
CA3058807A1 true CA3058807A1 (en) 2018-10-11

Family

ID=62063214

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3058807A Pending CA3058807A1 (en) 2017-04-03 2018-04-03 Protein antigens and uses thereof

Country Status (6)

Country Link
US (2) US12303561B2 (https=)
EP (1) EP3606550A2 (https=)
JP (3) JP7457642B2 (https=)
CN (2) CN118370809A (https=)
CA (1) CA3058807A1 (https=)
WO (1) WO2018187356A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
PL3429618T3 (pl) 2016-03-16 2024-07-01 Amal Therapeutics Sa Kombinacja modulatora immunologicznego punktu kontrolnego i kompleks zawierający peptyd penetrujący komórkę, cargo i agonistę peptydu tlr do zastosowania w medycynie
HUE067838T2 (hu) 2016-09-21 2024-11-28 Amal Therapeutics Sa Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére
WO2018187515A1 (en) 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
EP3634449A4 (en) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. ALPHAVIRUS NEOANTIGEN VECTORS
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
US20220273789A1 (en) * 2019-07-21 2022-09-01 Glaxosmithkline Biologicals Sa Therapeutic viral vaccine
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
CN113493494B (zh) * 2020-03-20 2022-08-16 上海交通大学医学院附属瑞金医院 Eb病毒balf3蛋白的抗原表位
EP3903811A1 (en) * 2020-05-01 2021-11-03 R.G.C.C. Holdings AG Pharmaceutical composition and method for inducing an immune response
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
CN112194719A (zh) * 2020-09-01 2021-01-08 中日友好医院(中日友好临床医学研究所) Crt抗原和mage-a1抗原的制备及其应用
WO2022098684A1 (en) * 2020-11-04 2022-05-12 The Trustees Of Columbia University In The City Of New York Immunosuppressive agents
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
CN114907473A (zh) * 2021-02-10 2022-08-16 厦门大学 用于预防和治疗eb病毒感染及相关疾病的表位肽及抗体
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
CN114128714B (zh) * 2021-12-07 2023-05-02 昆明学院 一种提高葡萄耐铝毒胁迫的药剂及处理方法
US20250054576A1 (en) * 2021-12-17 2025-02-13 Evaxion Biotech A/S Personalized cancer therapy targeting normally non-expressed sequences
CN120500492A (zh) * 2022-12-02 2025-08-15 西雅图项目公司 组合物及其使用方法

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0452457B1 (en) 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
WO1994003205A1 (en) 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
BR9406652A (pt) 1993-03-05 1996-09-10 Cytel Corp Composição
DE69435171D1 (de) 1993-09-14 2009-01-08 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
FR2753627B1 (fr) 1996-09-20 2003-02-21 Galderma Rech Dermatologique Utilisation des inhibiteurs de l'activite de l'acide retinoique pour favoriser la cicatrisation
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
NO309798B1 (no) 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
ATE512666T1 (de) 1999-06-29 2011-07-15 Epimmune Inc Hla-bindende peptide und ihre verwendungen
CA2384987A1 (en) 1999-09-16 2001-03-22 Zycos Inc. Nucleic acids encoding polyepitope polypeptides
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
WO2001055177A2 (en) 2000-01-28 2001-08-02 Statens Serum Institut Methods to identify ctl epitopes of hiv
CA2343602A1 (en) 2000-04-18 2001-10-18 Genset Est's and encoded human proteins
NZ523408A (en) * 2000-06-26 2006-02-24 Stressgen Biotechnologies Corp Human papilloma virus treatment
DE10037759A1 (de) 2000-08-03 2002-07-04 Gruenenthal Gmbh Screeningverfahren
CA2425648A1 (en) * 2000-10-19 2002-04-19 Epimmune Inc. Hla class i and ii binding peptides and their uses
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
WO2003004989A2 (en) 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
EP1338606A1 (en) * 2002-02-22 2003-08-27 Magnus Von Knebel Doeberitz Nucleic Acid encoding an HERV-H polypeptide for diagnosing colorectal cancer
EP1498145A4 (en) 2002-04-24 2005-08-10 Ginkgo Biomedical Res Inst Co LURE FOR THE TREATMENT AND / OR PREVENTION OF ALLERGIC DISEASE ASSOCIATED WITH CYTOKINE TH2, MUTANT PROTEIN GATA3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
WO2004011650A2 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
AU2003284239B2 (en) * 2002-10-21 2008-08-21 Eisai Inc. Compositions and methods for treating human papillomavirus-mediated disease
CA2536735C (en) * 2003-09-05 2013-01-22 Genencor International, Inc. Methods for determining cd8+ t-cell epitopes
US8673634B2 (en) 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
GB0413688D0 (en) 2004-06-18 2004-07-21 Novartis Forschungsstiftung Analysis of methylated nucleic acid
CA2588295C (en) 2004-11-23 2013-10-22 Adamas Pharma, Llc Method and composition for administering an nmda receptor antagonist to a subject
CN1299769C (zh) 2005-01-31 2007-02-14 中国医学科学院肿瘤医院肿瘤研究所 人乳头瘤病毒和热休克蛋白重组蛋白疫苗及其用途
US8252893B2 (en) * 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
JP4824389B2 (ja) 2005-10-28 2011-11-30 株式会社医学生物学研究所 エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途
WO2007140958A2 (en) 2006-06-02 2007-12-13 Glaxosmithkline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy
WO2008011120A2 (en) * 2006-07-21 2008-01-24 The Regents Of The University Of California Human endogenous retrovirus polypeptide compositions and methods of use thereof
KR101323540B1 (ko) 2007-02-07 2013-10-29 사이단호진한다이비세이부쯔뵤우겐큐우카이 암의 치료제
US8501167B2 (en) 2007-03-19 2013-08-06 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
EP2071334A1 (en) 2007-12-14 2009-06-17 Transmedi SA Compositions and methods of detecting TIABS
DE102008010954A1 (de) 2008-02-25 2009-08-27 Cichon, Günter, Prof.Dr. DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen
EP2105511A1 (en) 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung
CA2738031C (en) 2008-09-22 2022-11-29 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters
CN101885778B (zh) 2009-05-13 2013-10-16 中国疾病预防控制中心病毒病预防控制所 Hpv16型l2n120e7e6融合蛋白、基因、制备方法及用途
PE20121359A1 (es) 2009-12-10 2012-10-15 Merck Patent Gmbh Composicion farmaceutica que comprende oligopeptidos
WO2011073215A2 (en) 2009-12-14 2011-06-23 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
US9862927B2 (en) 2010-01-22 2018-01-09 Baylor Research Institute Dendritic cell vaccines
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
EP2569633B1 (en) 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
CA2801314A1 (en) 2010-06-02 2011-12-08 Abraxis Bioscience, Llc Methods of treating bladder cancer
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
GB2487632B (en) 2011-01-14 2014-03-12 Genefirst Ltd Methods,compositions,and kits for determining the presence/absence of a variant nucleic acid sequence
EP2478915A1 (en) 2011-01-24 2012-07-25 Genticel CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses
US8999937B2 (en) 2011-02-28 2015-04-07 Indiana University Research And Technology Corporation Glucocorticoid induced leucine zipper mimetics as therapeutic agents in multiple sclerosis
PL3892295T3 (pl) 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
CN103906848B (zh) 2011-08-18 2016-03-02 雀巢产品技术援助有限公司 用于检测等位变体的组合物和方法
AU2012309830B2 (en) 2011-09-15 2017-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing HLA-A1- or HLA-Cw7-restricted mage
WO2013086464A1 (en) 2011-12-07 2013-06-13 The Broad Institute, Inc. Markers associated with chronic lymphocytic leukemia prognosis and progression
US20130210014A1 (en) 2012-02-10 2013-08-15 Jeff Sharman Method for determining the prognosis and therapeutic response in chronic lymphocytic leukemia (cll) patients
WO2013123031A2 (en) 2012-02-15 2013-08-22 Veridex, Llc Highly sensitive method for detecting low frequency mutations
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
EP2844743B1 (en) 2012-05-03 2021-01-13 Fred Hutchinson Cancer Research Center Enhanced affinity t cell receptors and methods for making the same
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
BR112014029417B1 (pt) 2012-05-25 2023-03-07 Cellectis Método ex vivo para a preparação de células t para imunoterapia
WO2014012051A1 (en) 2012-07-12 2014-01-16 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
US20150140019A1 (en) 2012-07-13 2015-05-21 The Trustees Of The University Of Pennsylvania Compositions and Methods for Regulating CAR T Cells
KR102499753B1 (ko) 2012-07-27 2023-02-16 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 Ｔ 세포 수용체 조작
WO2014056986A1 (en) 2012-10-11 2014-04-17 Universitat De Barcelona Method to predict the clinical evolution of a patient suffering of chronic lymphocytic leukemia (cll)
CN113684185A (zh) 2013-02-26 2021-11-23 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
US10176294B2 (en) 2013-03-15 2019-01-08 The Broad Institute, Inc. Accurate typing of HLA through exome sequencing
US20160215042A1 (en) 2013-04-19 2016-07-28 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins
AU2014266833B2 (en) 2013-05-13 2020-07-02 Cellectis Methods for engineering highly active T cell for immunotherapy
WO2014191128A1 (en) 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
EP3293275B1 (en) 2013-06-06 2021-08-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
US20160310584A1 (en) 2013-12-06 2016-10-27 The Broad Institute Inc. Formulations for neoplasia vaccines
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
EA201691443A1 (ru) 2014-01-17 2016-12-30 Дбв Текнолоджиз Накожное восстановление иммунобаланса
EP3110971B1 (en) 2014-02-27 2019-05-08 The Broad Institute Inc. T cell balance gene expression and methods of use thereof
US20160252511A1 (en) 2014-03-14 2016-09-01 Brian J. Czemiecki Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
US20170261508A1 (en) 2014-03-14 2017-09-14 The Trustees Of The University Of Pennsylvania Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
EP3152569B1 (en) 2014-06-05 2020-06-10 AIMM Therapeutics B.V. Means and methods for determining t cell recognition
AU2015292246A1 (en) 2014-07-23 2017-02-23 Deakin University Antagonistic peptides
DK3198026T3 (da) 2014-08-07 2020-01-20 Pharmassist Ltd Fremgangsmåde til bestemmelse af pik3ca-mutationsstatus i en prøve
CN107073070A (zh) * 2014-08-15 2017-08-18 格纳西尼有限公司 治疗宫颈癌的方法
RS58080B1 (sr) 2014-11-04 2019-02-28 Janssen Vaccines & Prevention Bv Terapeutske vakcine protiv hpv16
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
WO2016123285A1 (en) * 2015-01-29 2016-08-04 The Trustees Of The University Of Pennsylvania Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy
EP3265562A4 (en) 2015-03-05 2018-12-19 TrovaGene, Inc. Early assessment of mechanism of action and efficacy of anti-cancer therapies using molecular markers in bodily fluids
EP3267969A1 (en) 2015-03-09 2018-01-17 King's College London Combination therapy with rar alpha agonists for enhancing th1 response
EP3075389A1 (en) 2015-03-31 2016-10-05 Technische Universität München T cell receptors and peptides derived by mutations for the treatment of cancer
US20190099475A1 (en) 2015-04-08 2019-04-04 Nantomics, Llc Cancer neoepitopes
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
WO2016203577A1 (ja) 2015-06-17 2016-12-22 株式会社医学生物学研究所 細胞傷害性ｔ細胞エピトープペプチド及びその用途
WO2017004153A1 (en) 2015-06-29 2017-01-05 The Broad Institute Inc. Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
WO2017011710A2 (en) 2015-07-14 2017-01-19 Whitehead Institute For Biomedical Research Chromosome neighborhood structures and methods relating thereto
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
EP3368687B1 (en) 2015-10-27 2021-09-29 The Broad Institute, Inc. Compositions and methods for targeting cancer-specific sequence variations
AU2016361451B2 (en) 2015-11-27 2024-01-25 Cartherics Pty. Ltd. Genetically modified cells and uses thereof
WO2017139694A1 (en) 2016-02-12 2017-08-17 Nantomics, Llc High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies
CN105693828A (zh) 2016-02-17 2016-06-22 深圳市中美康士生物科技有限公司 一种新的eb病毒ebna1表位肽及其在ebv相关疾病的诊断、治疗和预防中的用途
GB201603568D0 (en) 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
JP2019513373A (ja) 2016-03-31 2019-05-30 ネオン セラピューティクス， インコーポレイテッド ネオ抗原およびその使用方法
EP4628587A3 (en) 2016-04-15 2026-02-25 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
WO2018037416A1 (en) 2016-08-25 2018-03-01 Yeda Research And Development Co. Ltd. Methods and compositions for treating autoimmune diseases
CA3040337A1 (en) * 2016-10-26 2018-05-03 Curevac Ag Lipid nanoparticle mrna vaccines
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2020000587A1 (zh) 2018-06-26 2020-01-02 龚浩 一种方便清洁的灭虫灯

Also Published As

Publication number Publication date
US12303561B2 (en) 2025-05-20
JP2023106599A (ja) 2023-08-01
JP2020515640A (ja) 2020-05-28
JP7457642B2 (ja) 2024-03-28
JP2025084910A (ja) 2025-06-03
CN118370809A (zh) 2024-07-23
WO2018187356A2 (en) 2018-10-11
US20230241207A1 (en) 2023-08-03
US20260048116A1 (en) 2026-02-19
EP3606550A2 (en) 2020-02-12
WO2018187356A3 (en) 2018-11-01
CN111093691A (zh) 2020-05-01

Similar Documents

Publication Publication Date Title
US12303561B2 (en) Protein antigens and uses thereof
AU2021269272B2 (en) Neoantigens and methods of their use
CA3103883A1 (en) Neoantigens and uses thereof
WO2019246286A1 (en) Neoantigens and uses thereof
HK40113603A (zh) 蛋白质抗原及其用途
RU2773273C2 (ru) Неоантигены и способы их использования
HK40029579A (en) Protein antigens and uses thereof
HK40086688A (zh) 新抗原及其使用方法
HK40004257A (en) Neoantigens and methods of their use
NZ786786A (en) Neoantigens and methods of their use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250320

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250904

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260319

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260319